RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Vascular Biogenics Stock

Vascular Biogenics Liabilities 2024

Vascular Biogenics Liabilities

7.21 M USD

Ticker

VBLT

ISIN

IL0011327454

WKN

A119YE

In 2024, Vascular Biogenics's total liabilities amounted to 7.21 M USD, a -42.26% difference from the 12.48 M USD total liabilities in the previous year.

Vascular Biogenics Aktienanalyse

What does Vascular Biogenics do?

Vascular Biogenics Ltd (VBL) is a biopharmaceutical company that was founded in 2000. The company is headquartered in Modi'in, Israel and is listed on the NASDAQ under the ticker symbol "VBLT". The history of VBL dates back to the discovery of a protein called Vascular Endothelial Growth Factor-B (VEGF-B) by the company's founder, Professor Moshe Deutsch. VEGF-B is considered a key regulator in blood vessel formation and diseases such as cancer, macular degeneration, and arteriosclerosis. VBL's business model is based on the development and commercialization of novel therapies based on the use of VEGF-B. The company focuses on the development of cancer therapies as well as the treatment of eye diseases and inflammatory diseases. VBL is divided into three divisions: 1. Oncology: In this division, VBL is developing a novel therapy for the treatment of cancer based on a encapsulated version of VEGF-B. This therapy aims to slow tumor growth and activate the patient's immune system to fight the tumor. VBL currently has several ongoing clinical trials that show promising results. 2. Ophthalmology: In this division, VBL is investigating the use of VEGF-B in the treatment of macular degeneration, an eye disease that can lead to vision loss. The company has developed a drug called "VB-421" that has been successfully tested in clinical trials. 3. Inflammatory diseases: VBL is also working on the development of therapies for inflammatory diseases such as rheumatism and colitis. The company also uses the VEGF-B active ingredient for this purpose. In recent years, VBL has already brought several drugs to the market and is continuously working on the development of new therapies. The company collaborates closely with various universities and research institutions. Overall, VBL has achieved promising results in research in recent years and has conducted numerous successful clinical trials. The company focuses on the development of therapies for severe diseases for which there is currently no effective treatment. VBL aims to improve the lives of patients worldwide and make great progress in medicine. Vascular Biogenics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Vascular Biogenics's Liabilities

Vascular Biogenics's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Vascular Biogenics's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Vascular Biogenics's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Vascular Biogenics's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Vascular Biogenics’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Vascular Biogenics stock

What is the level of liabilities of Vascular Biogenics this year?

Vascular Biogenics has a debt balance of 7.21 M USD this year.

What were the liabilities of Vascular Biogenics compared to the previous year?

The liabilities of Vascular Biogenics have increased by -42.26% dropped compared to the previous year.

What are the consequences of high debt for investors of Vascular Biogenics?

High liabilities can pose a risk for investors of Vascular Biogenics, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Vascular Biogenics?

Low liabilities mean that Vascular Biogenics has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Vascular Biogenics affect the company?

An increase in liabilities of Vascular Biogenics can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Vascular Biogenics affect the company?

A decrease in the liabilities of Vascular Biogenics can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Vascular Biogenics?

Some factors that can influence the liabilities of Vascular Biogenics include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Vascular Biogenics so important for investors?

The liabilities of Vascular Biogenics are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Vascular Biogenics take to modify the liabilities?

To change its liabilities, Vascular Biogenics can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Vascular Biogenics pay?

Over the past 12 months, Vascular Biogenics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Vascular Biogenics is expected to pay a dividend of 0 USD.

What is the dividend yield of Vascular Biogenics?

The current dividend yield of Vascular Biogenics is .

When does Vascular Biogenics pay dividends?

Vascular Biogenics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Vascular Biogenics?

Vascular Biogenics paid dividends every year for the past 0 years.

What is the dividend of Vascular Biogenics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Vascular Biogenics located?

Vascular Biogenics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Vascular Biogenics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Vascular Biogenics from 11/12/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/12/2024.

When did Vascular Biogenics pay the last dividend?

The last dividend was paid out on 11/12/2024.

What was the dividend of Vascular Biogenics in the year 2023?

In the year 2023, Vascular Biogenics distributed 0 USD as dividends.

In which currency does Vascular Biogenics pay out the dividend?

The dividends of Vascular Biogenics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Vascular Biogenics

Our stock analysis for Vascular Biogenics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Vascular Biogenics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.